AI-driven precision cancer treatment: Multimodal data integration and real-time decision support for personalized oncology medication

Artificial intelligence (AI) can be used to enhance precision oncology by utilizing multimodal data and real-time data provision to enhance cancer care. The analysis of digital pathology images is performed by AI, which allows for the definition of genetic traits to reduce the costs of genetic tests and save a substantial amount of money when diagnosing patients. In addition, AI in liquid biopsies helps to identify small residual disease earlier than conventional techniques do, which translates to more effective cancer progression monitoring. State-of-the-art technologies such as MR-Linacs and surgical robots apply AI to alter radiation therapy in real time and assist in cancer procedures immediately. AI systems can be used to provide treatment recommendations, such as IBM Watson, which is used to support decisions made by healthcare providers when treating patients. Recent precise oncology research has significantly improved the accuracy of predictions of treatment outcomes and the discovery of new markers, although with challenges such as data variability and model interpretation. Artificially intelligent systems have already proven to be effective in accurately predicting the response of patients to treatments and finding new means of disease prognosis in accurate oncology environments. AI systems need to be transparent so that trust is built and maintained with health service providers and patients to hold them accountable. To ensure fair and ethical use of AI in cancer care in the future, it is necessary to conduct thorough validation work, treat bias as a systematic issue, and maintain a high level of ethical standards to ensure that decisions made under the banner of AI are unbiased and that the results of the work are ethical to the maximum.